Suchergebnisse - "Cook, Gordon"

PubPharm (409)

61

Health-related quality of life in patients with relapsed or refractory multiple myeloma : treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

enthalten in: British journal of haematology | 2021

von Plesner, T. | Dimopoulos, M. | Oriol, A. | +15

62

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

enthalten in: Haematologica | 2021

von Jackson, G. | Davies, F. | Pawlyn, C. | +21

63

Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial

enthalten in: Leukemia | 2021

von Croft, J. | Ellis, S. | Sherborne, A. | +19

64

Efficacy and safety profile of deep responders to carfilzomib-based therapy : a subgroup analysis from ASPIRE and ENDEAVOR

enthalten in: Leukemia | 2021

von Weisel, K. | Mateos, M. | Gay, F. | +6

65

Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma : Results of an Early Access Treatment Protocol in Europe and Russia

enthalten in: Oncology and therapy | 2021

von Cook, G. | Corso, A. | Streetly, M. | +11

66

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

enthalten in: Annals of hematology | 2021

von Davies, F. | Rifkin, R. | Costello, C. | +24

67

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

enthalten in: Annals of hematology | 2021

von Davies, F. | Rifkin, R. | Costello, C. | +24

68

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

enthalten in: Annals of hematology | 2021

von Davies, F. | Rifkin, R. | Costello, C. | +24

69

Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma

enthalten in: British journal of haematology | 2021

von Bygrave, C. | Pawlyn, C. | Davies, F. | +11

70

Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study

enthalten in: British journal of haematology | 2021

von Camilleri, M. | Cuadrado, M. | Phillips, E. | +21